Curated News
By: NewsRamp Editorial Staff
March 23, 2026
Viromed Secures Major Funding for Revolutionary Cold Plasma Medical Tech
TLDR
- Viromed Medical AG gains a high six-figure euro funding advantage to develop pioneering cold plasma systems, potentially leading the market in non-pharmacological infection treatments.
- Viromed Medical AG's funding supports developing PulmoPlas for lung germ inactivation and ViroCap for wound healing, using cold atmospheric plasma technology to address medical challenges.
- Viromed's cold plasma technology aims to improve intensive care and wound healing, potentially saving lives and reducing suffering from infectious diseases.
- Cold plasma technology, funded for medical use, can inactivate germs in lungs and heal wounds without drugs, showcasing innovative science in action.
Impact - Why it Matters
This development matters because it accelerates the availability of potentially transformative medical technologies that could significantly improve patient outcomes in critical care settings. Cold plasma technology represents a non-pharmacological approach to infection control, addressing the growing global challenge of antimicrobial resistance and hospital-acquired infections. The PulmoPlas® system specifically targets respiratory infections, which remain a leading cause of mortality in intensive care units worldwide. By providing alternative treatment modalities that don't rely on traditional antibiotics, these innovations could help combat drug-resistant pathogens while reducing healthcare costs associated with prolonged hospital stays and complex infection management. For patients, this means potentially faster recovery times, reduced risk of complications, and access to more effective treatments for serious infections.
Summary
Viromed Medical AG, a pioneering medical technology company specializing in cold plasma technology, has secured significant funding approval from Germany's Federal Ministry of Research, Technology and Space. The certification, granted under the Research Allowance Act (FZulG), provides funding in the high six-figure euro range, underscoring the scientific and technological relevance of Viromed's innovative solutions. This financial support will accelerate the development of two groundbreaking medical systems: PulmoPlas®, a stationary system designed for integration into ventilation processes to selectively inactivate pathogenic germs in the lower respiratory tract, and ViroCap®, a mobile device for contact-free plasma application to support wound healing. Both projects address critical medical challenges and expand the current state of the art, particularly in intensive care medicine and infection control.
The funding represents a major validation of Viromed's strong innovative capabilities and positions the company at the forefront of non-pharmacological treatment approaches for infectious diseases. Notably, the application of cold plasma in the lungs through PulmoPlas® represents a novel therapeutic approach for which no comparable systems currently exist, potentially revolutionizing how respiratory infections are managed in clinical settings. As a publicly traded company listed since October 2022, Viromed operates through its wholly owned subsidiary Viromed Medical GmbH, serving a broad customer base across the DACH region and beyond. The company's strategic focus on advancing cold plasma technology in medicine aligns with growing global demand for innovative infection control solutions.
This development news was originally released on www.newmediawire.com, highlighting Viromed's commitment to transforming medical treatment through cutting-edge technology. The funding approval not only strengthens Viromed's market position but also accelerates the timeline for bringing these potentially life-saving technologies to healthcare providers and patients. With contact information available through their official website and press contacts, Viromed continues to drive innovation in medical technology while addressing some of healthcare's most persistent challenges through scientific advancement and strategic partnerships.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Viromed Secures Major Funding for Revolutionary Cold Plasma Medical Tech
